Company profile
Gyre Therapeutics, Inc.
NASDAQ: GYRE · Healthcare · Biotechnology
#334 of 1,422 Healthcare companies by revenue56th-percentile growth
EA Score
72BFH 82DQ 72GM 39SS 79
v0.1 · 65/100 weight · provisional
↑ Altman-Z, return on assets · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$117.0M
Rev growth YoY (TTM)
+16.3%
Net income (FY)
$9.9M
Employees
625
as of 2026-08-11
Market cap
$614.1M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$116.6M$116.6M2025
Net income$9.9M$9.9M2025
Operating income$11.5M$11.5M2025
Total assets$166.1M$166.1M2025
Liabilities$23.9M$23.9M2025
Equity$106.0M$106.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY18
FY20
FY21
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Product100%
By geography
Not disclosed.
The read
What is Gyre Therapeutics, Inc.’s revenue?
Gyre Therapeutics, Inc. booked $116.6M in FY2025 revenue, growing 10% year over year — about the middle of the pack among Healthcare companies we track, at a 8.5% net margin.
Peers · Healthcare
SmileDirectClub Inc Class A——Outset Medical, Inc.52DNortech Systems Incorporated71BOraSure Technologies, Inc.67BAgenus Inc.67BImmunityBio, Inc.58CNeighbors
San Diego →Key facts
CEOYing Luo
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: GYRE
Employees625
IPO date2006-04-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.